Dies ist eine Übersichtsseite mit Metadaten zu dieser wissenschaftlichen Arbeit. Der vollständige Artikel ist beim Verlag verfügbar.
FDG PET/CT for assessing tumour response to immunotherapy
260
Zitationen
6
Autoren
2018
Jahr
Abstract
This paper follows the immunotherapy symposium held during the European Association of Nuclear Medicine (EANM) 2017 Annual Congress. The biological basis of the immune checkpoint inhibitors and the drugs most frequently used for the treatment of solid tumours are reviewed. The issues of pseudoprogression (frequency, timeline), hyperprogression and immune-related side effects are discussed, as well as their implications for patient management. A review of the recent literature on the use of FDG PET for assessment of immunotherapy is presented, and recommendations are provided for assessing tumour response and reporting immune-related side effects with FDG PET based on published data and experts' experience. Representative clinical cases are also discussed.
Ähnliche Arbeiten
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
2016 · 30.917 Zit.
AJCC Cancer Staging Manual
2016 · 17.410 Zit.
Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review
2017 · 15.284 Zit.
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
2010 · 15.084 Zit.
The blockade of immune checkpoints in cancer immunotherapy
2012 · 13.640 Zit.
Autoren
Institutionen
- Inserm(FR)
- European Association of Nuclear Medicine(AT)
- Normandie Université(FR)
- Centre Hospitalier Universitaire de Caen Normandie(FR)
- Université de Caen Normandie(FR)
- The University of Melbourne(AU)
- Peter MacCallum Cancer Centre(AU)
- Institut Curie(FR)
- University of Toronto(CA)
- Princess Margaret Cancer Centre(CA)
- IRCCS Azienda Ospedliero-Universitaria di Bologna Policlinico di Sant'Orsola(IT)
- University of Bologna(IT)